Sanofi (SAN) PT Set at €92.00 by Morgan Stanley

Morgan Stanley set a €92.00 ($106.98) target price on Sanofi (EPA:SAN) in a research note published on Thursday, October 26th. The firm currently has a buy rating on the stock.

Several other equities analysts have also weighed in on SAN. Credit Suisse Group set a €95.00 ($110.47) price objective on Sanofi and gave the company a buy rating in a research note on Tuesday, July 4th. J P Morgan Chase & Co reissued a neutral rating on shares of Sanofi in a research report on Thursday, July 20th. Goldman Sachs Group, Inc. (The) set a €82.00 ($95.35) price target on Sanofi and gave the stock a neutral rating in a research report on Wednesday, July 26th. Kepler Capital Markets set a €89.00 ($103.49) price target on Sanofi and gave the stock a buy rating in a research report on Wednesday, July 26th. Finally, S&P Global set a €90.00 ($104.65) target price on Sanofi and gave the company a neutral rating in a research report on Monday, July 31st. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have assigned a buy rating to the stock. Sanofi has a consensus rating of Hold and an average target price of €87.24 ($101.44).

Shares of Sanofi (EPA SAN) opened at €77.43 ($90.03) on Thursday. Sanofi has a fifty-two week low of €73.39 ($85.34) and a fifty-two week high of €92.97 ($108.10).

ILLEGAL ACTIVITY NOTICE: This report was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2017/11/12/sanofi-sa-san-given-a-92-00-price-target-at-morgan-stanley-2.html.

About Sanofi

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi (EPA:SAN)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply